Comparison
Tesamorelin vs. Thymosin Alpha-1
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Healing
CAS no.
901758-09-6
62304-98-7
Molecular weight
5135.83 g/mol
3108.32 g/mol
Half-life
0.4 h
2 h
Sequence
trans-3-hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2Ac-SDAAVDTSSEITTKDLKEKKEVVEEAENMechanism of action
Tesamorelin
Tesamorelin is an N-terminally modified 44-amino-acid version of human GHRH(1-44). A 3-hexenoyl modification protects against rapid dipeptidyl-peptidase-IV cleavage. Binding to the pituitary GHRH receptor stimulates endogenous pulsatile growth-hormone secretion and consequently hepatic IGF-1 production.
Thymosin Alpha-1
Thymosin Alpha-1 is an N-terminally acetylated peptide originally isolated from the thymus. It modulates T-lymphocyte maturation and function and acts on dendritic cells via Toll-like receptors (TLR9 / TLR2). In preclinical and some clinical studies, increased interferon-gamma responses and altered T-cell subpopulations have been reported.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
2
2
of which in humans
2
2
Effects recorded
3
3
Open conflicts
0
1
Documented adverse events
2
1